Company: INMB
Filing Date: 2025-06-30
Form Type: 424B5
Source: 0001213900-25-059298
Chunk: 27

Company: Inmune Bio, Inc.
Filing Date: 2025-06-30
Form: 424B5
Chunk 27
---
 remains after treatment with cytotoxic therapy.

Likewise, we believe XPro1595,
our microglial directed therapy, offers a unique strategy to decrease neuroinflammation, a key pathophysiology in neurodegenerative and
neuropsychiatric diseases. XPro1595 will use a precision medicine approach to select patients who will benefit from the therapy and monitor
the response to the therapy. The therapy is not diagnosis specific but will be used in patients who have biomarkers of neuroinflammation.
Our initial program with XPro1595 will be treating patients with Alzheimer’s disease with biomarkers inflammation.

Likewise, we believe LivNate,
our HSC directed therapy, offers a unique strategy to treat NASH by decreasing peripheral, regional and local inflammatory cycles that
results in hepatocyte ballooning and death, hepatitis and fibrosis, the core pathophysiology of many inflammatory liver diseases. Our
initial program with LivNate will be treating patients with NASH.

We reported a net loss of
$12,099,159 and $7,678,313 for the years ended December 31, 2020 and 2019, respectively. We have an accumulated deficit of $33,375,340
as of December 31, 2020.

<div align='center'>3</div>

Implications of Being an Emerging Growth Company and a Smaller Reporting Company

As a company with less than
$1.07 billion in revenue during our last fiscal year, we qualify as an “emerging growth company,” as defined in the Jumpstart
Our Business Startups Act of 2012, or the JOBS Act. An emerging growth company may take advantage of reduced reporting requirements that
are otherwise applicable to public companies. These provisions include, but are not limited to:

| ● | being permitted to present only two years of audited financial                                                             
 statements and two years of related Management’s Discussion and Analysis of Financial Condition and Results of Operations; |

| ● | not being required to comply with the auditor attestation                                                
 requirements of Section 404(b) of the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act; |

| ● | reduced disclosure obligations regarding executive compensation        
 in periodic reports, proxy statements and registration statements; and |

| ● | exemptions from the requirements of holding a nonbinding advisory                                                 
 vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. |

We may take advantage